PHARMACOLOGICAL TREATMENT OF VULVOVAGINAL, ESOPHAGEAL AND URINARY TRACT CANDIDIASIS

Abstract

Introduction: Candidiasis is a fungal infection caused by the Candida fungus and covers a wide variety of clinical manifestations. One of the fundamental tools in the treatment of this infection is the use of the antifungal fluconazole. The dosage and duration of treatment vary depending on the form of the infection. Objective: This article involved a critical analysis of research to identify trends, knowledge gaps, and current challenges associated with candidiasis, with an emphasis on the efficacy of fluconazole. Methodology: This research aims to deepen the understanding of candidiasis, providing valuable information for healthcare professionals and researchers facing the clinical challenges of this fungal infection. It is a species that is naturally sensitive to all systemic antifungal drugs, but cases of acquired resistance to azoles are known in patients exposed to these medications for a prolonged period. Final Considerations: Fluconazole interacts with 14-α-sterol-demethylase, a cytochrome P-450 enzyme responsible for catalyzing the conversion of ianosterol into ergosterol. The demethylation mechanism in mammals is less sensitive to the action of fluconazole, therefore the drug helps the body to neutralize the agents that cause fungal infection.